Wang, Hao
Ishchenko, Andrii http://orcid.org/0000-0002-3797-0604
Skudlarek, Jason http://orcid.org/0000-0002-5847-9144
Shen, Pamela
Dzhekieva, Liudmila
Painter, Ronald E.
Chen, Yun-Ting
Bukhtiyarova, Marina
Leithead, Andrew
Tracy, Rodger
Babaoglu, Kerim
Bahnck-Teets, Carolyn
Buevich, Alexei
Cabalu, Tamara D.
Labroli, Marc
Lange, Henry
Lei, Ying
Li, Wei
Liu, Jian
Mann, Paul A.
Meng, Tao
Mitchell, Helen J.
Mulhearn, James
Scapin, Giovanna
Sha, Deyou
Shaw, Anthony W.
Si, Qian
Tong, Ling
Wu, Chengwei
Wu, Zhe
Xiao, Jing Chen
Xu, Min http://orcid.org/0000-0002-3317-7561
Zhang, Li-Kang
McKenney, David
Miller, Randy R.
Black, Todd A.
Cooke, Andrew
Balibar, Carl J.
Klein, Daniel J.
Raheem, Izzat http://orcid.org/0000-0002-6769-8816
Walker, Scott S. http://orcid.org/0000-0002-3076-439X
Article History
Received: 22 November 2023
Accepted: 6 March 2024
First Online: 22 April 2024
Competing interests
: All authors are or were, at the time this work was conducted, employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may be shareholders in Merck & Co., Inc., Rahway, NJ, USA. Cerastecin A–D are the subjects of two patent applications (PCT/US2023/022198 and PCT/US2023/022200) by Merck Sharp & Dohme LLC, Rahway, NJ, USA. I.R., C.J.B., J.S., M.L., H.J.M., L.T., H.W., C.W., A.B., L.-K.Z., J.L., K.B., Z.W., A.W.S. and A.C. are inventors on either or both applications.